Manjusha Gaglani
Overview
Explore the profile of Manjusha Gaglani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
195
Citations
7172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frutos A, Cleary S, Reeves E, Ahmad H, Price A, Self W, et al.
MMWR Morb Mortal Wkly Rep
. 2025 Feb;
74(6):83-90.
PMID: 40014791
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits...
2.
Yousaf A, Mak J, Gwynn L, Lutrick K, Bloodworth R, Rai R, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2459672.
PMID: 39992656
Importance: An estimated 1% to 3% of children with SARS-CoV-2 infection will develop post-COVID-19 condition (PCC). Objective: To evaluate the odds of PCC among children with COVID-19 vaccination prior to...
3.
Khan A, Zhu Y, Babcock H, Busse L, Duggal A, Exline M, et al.
Vaccine
. 2025 Jan;
48:126806.
PMID: 39884913
Background: Understanding similarities and differences between hesitancy for influenza and COVID-19 vaccines could facilitate strategies to improve public receptivity toward vaccination. Methods: We compared hesitancy for COVID-19 vaccines during the...
4.
Huang P, Nowalk M, Zimmerman R, Olson S, Talbot H, Zhu Y, et al.
Hum Vaccin Immunother
. 2025 Jan;
21(1):2457205.
PMID: 39875316
Influenza causes 100,000-710,000 hospitalizations annually in the U.S. Patients with liver disease are at higher risk of severe outcomes following influenza infection. This study evaluated influenza vaccine effectiveness (VE) against...
5.
Rowley E, Mitchell P, Yang D, Lewis N, Dixon B, Vazquez-Benitez G, et al.
JMIR Form Res
. 2025 Jan;
9:e58981.
PMID: 39869907
Background: Real-world COVID-19 vaccine effectiveness (VE) studies are investigating exposures of increasing complexity accounting for time since vaccination. These studies require methods that adjust for the confounding that arises when...
6.
Chung J, Price A, Zimmerman R, Moehling Geffel K, House S, Curley T, et al.
Clin Infect Dis
. 2025 Jan;
PMID: 39761230
Background: The 2023-24 U.S. influenza season was characterized by a predominance of A(H1N1)pdm09 virus circulation with co-circulation of A(H3N2) and B/Victoria viruses. We estimated vaccine effectiveness (VE) in the United...
7.
Hollister J, Porter C, Sprissler R, Beitel S, Romine J, Uhrlaub J, et al.
PLoS One
. 2024 Dec;
19(12):e0306953.
PMID: 39739951
The extent to which semi-quantitative antibody levels confer protection against SARS-CoV-2 infection in populations with heterogenous immune histories is unclear. Two nested case-control studies were designed within the multisite HEROES/RECOVER...
8.
Hughes Kramer K, Zimmerman R, Haggerty C, Balasubramani G, Nowalk M, Martin E, et al.
Hum Vaccin Immunother
. 2024 Dec;
20(1):2354013.
PMID: 39693194
While the number of immunocompromised (IC) individuals continues to rise, the existing literature on influenza vaccine effectiveness (VE) in IC populations is limited. Understanding the vaccine effectiveness (VE) of the...
9.
Park J, Bartzoka F, von Beck T, Li Z, Mishina M, Hebert L, et al.
Lancet Microbe
. 2024 Dec;
6(2):100935.
PMID: 39667375
Background: Egg-based inactivated quadrivalent seasonal influenza vaccine (eIIV4), cell culture-based inactivated quadrivalent seasonal influenza vaccine (ccIIV4), and recombinant haemagglutinin (HA)-based quadrivalent seasonal influenza vaccine (RIV4) have been licensed for use...
10.
Feldstein L, Ruffin J, Wiegand R, Grant L, Babu T, Briggs-Hagen M, et al.
J Pediatric Infect Dis Soc
. 2024 Dec;
14(1.
PMID: 39656907
To understand how coronavirus disease 2019 vaccines impact infection risk in children <5 years, we assessed risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from September 2022 to...